CIRM Funded Clinical Trials
Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis
Details:
Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded $8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage in areas damaged by osteoarthritis. CIRM funded the research that developed this technology and now this Phase 1 trial will test this stem cell directed treatment in people with osteoarthritis of the knee, hopefully slowing down or even halting the progression of the disease.
Design:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study.
Goal:
This study will evaluate the safety and tolerability of KA34 when administered to patients with osteoarthritis of the knee.
Updates:
Podcast - Dr. Kristen Johnson & Dr. Maria Millan: Regenerative Medicine for Osteoarthritis
Contact Trial Sponsor
